LFST übertreffen die 10 der letzten 18Schätzungen.
56%
Nächster Bericht
Datum des nächsten Berichts
26. Feb. 2026
Estimate forQ4 25(Revenue/ EPS)
$385.60M
/
$0.00
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+5.99%
/
--
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+18.47%
/
-100.00%
LifeStance Health Group, Inc. Common Stock earnings per share and revenue
On 06. Nov. 2025, LFST reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.01 USD, resulting in a 100.00% surprise. Revenue reached 363.81 million, compared to an expected 362.72 million, with a 0.30% difference. The market reacted with a +29.94% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 11 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 385.60 million USD, implying an increase of 0.00% EPS, and increase of 5.99% in Revenue from the last quarter.
FAQ
What were LifeStance Health Group, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, LifeStance Health Group, Inc. Common Stock reported EPS of $0.00, beating estimates by 100%, and revenue of $363.81M, 0.3% above expectations.
How did the market react to LifeStance Health Group, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 29.94%, changed from $4.81 before the earnings release to $6.25 the day after.
When is LifeStance Health Group, Inc. Common Stock expected to report next?
The next earning report is scheduled for 26. Feb. 2026.
What are the forecasts for LifeStance Health Group, Inc. Common Stock's next earnings report?
Based on 11
analysts, LifeStance Health Group, Inc. Common Stock is expected to report EPS of -- and revenue of $385.60M for Q4 2025.